Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
30 Novembro 2021 - 3:00AM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer, and
Taiho Pharmaceutical Co., Ltd., (“Taiho”), an R&D driven
specialty pharma company with a focus on oncology, today announced
that Taiho exercised its option for anti-TIGIT antibodies
domvanalimab (development code: AB154) and AB308 from Arcus
Biosciences (“Arcus”), in Japan and certain other territories in
Asia (excluding China). This option exercise is based on an option
and license agreement between Taiho and Arcus contracted in
September 2017. Taiho has already obtained exclusive rights to
etrumadenant (AB928), an adenosine A2a/A2b receptor antagonist, and
zimberelimab (AB122), an anti-PD-1 monoclonal antibody. This is the
third option exercise to an Arcus program.
In exchange for the exclusive license, Taiho will make an option
exercise payment, as well as additional payments upon achievement
of clinical, regulatory and commercialization milestones, and, if
any products from the program are approved, will pay royalties on
net sales of such products.
Domvanalimab is an Fc-silent anti-TIGIT antibody currently under
development by Arcus. Similar to PD-1, TIGIT is an immune
checkpoint receptor that is expressed on immune cells such as T
cells and NK cells. By binding to its ligand CD155, expressed on
tumor cells, TIGIT suppresses anti-tumor immune responses, which
are thought to be involved with poor prognosis in various types of
cancers. Domvanalimab is believed to activate anti-tumor immune
responses by blocking CD155 from binding to TIGIT, making it
possible for CD155 to bind to and trigger the activating receptor
CD226.
Domvanalimab is being developed primarily as a combination
therapy with anti-PDx checkpoint inhibitors. The Phase 2 (ARC-7)
and Phase 3 (ARC-10) trials of domvanalimab in combination with
zimberelimab are currently being conducted by Arcus in first-line
metastatic PD-L1≥50% non-small cell lung cancer. A Phase 3 trial
(PACIFIC-8) of domvanalimab in combination with durvalumab
(Imfinzi®, AstraZeneca) is being initiated in Stage III non-small
cell lung cancer. Development in other cancer types is also being
planned.
Through this collaboration, Taiho will further support the
development and commercialization of domvanalimab and will continue
its mission to deliver innovative drugs to patients and medical
professionals.
About AB308
AB308 is an Fc-enabled anti-TIGIT antibody currently under
development by Arcus. In combination with zimberelimab, AB308 is
being investigated in an ongoing Phase 1b trial in people with
advanced solid and hematologic malignancies.
About Zimberelimab
Zimberelimab is an anti-PD-1 monoclonal antibody currently under
development by Arcus. Preliminary data from clinical trials have
suggested that zimberelimab has an efficacy and safety profile
similar to that of other approved anti-PD-1 monoclonal
antibodies.
In addition to combination studies with domvanalimab, Arcus is
conducting Phase 1/2 clinical trials of zimberelimab in combination
with other Arcus programs in various types of cancers. In Japan,
Taiho is conducting a Phase 1 platform trial for zimberelimab in
combination with other Taiho products.
About Taiho Pharmaceutical
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd.,
is an R&D-driven specialty pharma focusing on the three fields
of oncology, allergy and immunology, and urology. Its corporate
philosophy takes the form of a pledge: “We strive to improve human
health and contribute to a society enriched by smiles.” In the
field of oncology in particular, Taiho Pharmaceutical is known as a
leading company in Japan for developing innovative medicines for
the treatment of cancer, a reputation that is rapidly expanding
through their extensive global R&D efforts. In areas other than
oncology, as well, the company creates and markets quality products
that effectively treat medical conditions and can help improve
people's quality of life. Always putting customers first, Taiho
Pharmaceutical also aims to offer consumer healthcare products that
support people's efforts to lead fulfilling and rewarding lives.
For more information about Taiho Pharmaceutical, please visit:
https://www.taiho.co.jp/en/.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well characterized biology and pathways and studying novel,
biology-driven combinations that have the potential to help people
with cancer live longer. Founded in 2015, the company has expedited
the development of six investigational medicines into clinical
studies, including new combination approaches that target TIGIT,
PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently,
HIF-2alfa. For more information about Arcus Biosciences’ clinical
and pre-clinical programs, please visit www.arcusbio.com or follow
us on Twitter.
Arcus Biosciences’ Forward-Looking Statements
This press release contains forward-looking statements. All
statements regarding events or results to occur in the future
contained herein, including, but not limited to, Arcus’s receipt of
milestones or royalties, the planning and initiation of additional
clinical development activities, and realization of any potential
benefits from this transaction, are forward-looking statements
reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements
involve known and unknown risks and uncertainties and other
important factors that may cause our actual results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Factors that could cause
or contribute to such differences include, but are not limited to:
difficulties associated with the management of the collaboration
activities or expanded clinical programs; risks associated with
preliminary and interim data; the unexpected emergence of adverse
events or other undesirable side effects; the inherent uncertainty
associated with the COVID-19 pandemic, including the duration
and/or severity of the pandemic and actions by government
authorities to contain or slow the spread of the virus; the
inherent uncertainty associated with pharmaceutical product
development and clinical trials; delays in Arcus’s clinical trials
due to difficulties or delays in the regulatory process, enrolling
subjects or manufacturing or supplying product for such clinical
trials; and changes in the competitive landscape for Arcus’s
programs. Risks and uncertainties facing Arcus are described more
fully in its quarterly report on Form 10-Q for the quarter ended
September 30, 2021, filed on November 8, 2021, with the SEC. You
are cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this press release.
Arcus disclaims any obligation or undertaking to update, supplement
or revise any forward-looking statements contained in this press
release.
The Arcus name and logo are trademarks of Arcus. All other
trademarks belong to their respective owners.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211129005788/en/
Investor and Media Inquiries: Holli Kolkey VP of
Corporate Communications (650) 922-1269 hkolkey@arcusbio.com
Taiho Pharmaceutical Misato Okubo Strategic Communications
th-koho@taiho.jp
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024